Phase I/II clinical trial - Hématologie Lymphome non Hodgkinien

Epi R-CHOP
Hématologie Lymphome non Hodgkinien
Ouvert depuis le: 12.08.2021
Site: Saint-Cloud
Public cible
Adulte
A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or High Risk Follicular Lymphoma (FL) Patients Treated by R-CHOP
Description de l'essai

Phase I of the study is designed to determine the recommended phase II dose (RP2D) for tazemetostat in patients treated with 8 cycles of R-CHOP 21.;Phase II of the study is designed to determine the safety and the efficacy of tazemetostat in DLBCL and FL patients :;DLBCL : tazemetostat with 6 cycles of R-CHOP 21 + 2 cycles of Rituximab FL : tazemetostat with 6 cycles of R-CHOP 21 + 2 cycles of Rituximab then maintenance with 6 months of tazemetostat and 24 months of Rituximab